Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Optimizing Metastatic Colorectal Cancer Care: From Clinical Evidence to Real-World Excellence : Episode 7
Incorporating Patient-Reported Outcomes in mCRC Into Shared Decision-Making
Panelists discuss how PROs, particularly tolerability and fatigue, guide shared decision-making for third-line therapy in mCRC.
EP: 1.Overview of Available Third-Line Options in mCRC
EP: 2.Evidence Supporting FTD/TPI ± Bevacizumab in mCRC
EP: 3.Efficacy of Fruquintinib and Comparisons Across Agents in mCRC
EP: 4.Selecting Among Third-Line Therapies in Clinical Practice for mCRC
EP: 5.Leveraging Real-World Evidence in Sequencing Decisions for mCRC
EP: 6.Translating Real-World Outcomes in mCRC Into Patient Conversations
Now Viewing
EP: 7.Incorporating Patient-Reported Outcomes in mCRC Into Shared Decision-Making
EP: 8.Real-World Evidence in mCRC: Special Populations and Safety Assessment
Panelists examine the value of patient-reported outcomes (PROs) in helping guide therapy selection for later-line metastatic colorectal cancer (mCRC). They stress the importance of domains such as gastrointestinal tolerability, fatigue, and functional status.
By integrating PRO data into discussions, clinicians can better align treatment strategies with patient priorities, ensuring quality of life remains central.
Systematic incorporation of PROs into routine practice can refine decision-making, helping clinicians anticipate challenges and patients feel more engaged in their care.
Related Videos
Related Content
